Development of an Oral IgA Response against SARS-CoV-2 Following Immunization with Different COVID-19 Vaccines
Authors:
- Irene SoffrittiISIrene Soffritti
- Maria D’accoltiMDMaria D’accolti
- Francesca BiniFBFrancesca Bini
- Eleonora MazzigaEMEleonora Mazziga
- Davide ProiettoDPDavide Proietto
- Beatrice DallanBDBeatrice Dallan
- Martina De LaurentisMLMartina De Laurentis
- Sara GhiselliniSGSara Ghisellini
- Francesco NicoliFNFrancesco Nicoli
- Elisabetta CaselliElisabetta Caselli
Open Access
Abstract
The mucosal immune response is recognized to be important in the early control of infection sustained by viruses with mucosal tissues as the primary site of entry and replication, such as SARS-CoV-2. Mucosal IgA has been consistently reported in the mouth and eye of SARS-CoV-2 infected subjects, where it correlated inversely with COVID-19 symptom severity. Yet, there is still scarce information on the comparative ability of the diverse SARS-CoV-2 vaccines to induce local IgA responses at the virus entry site. Thus, the aim of this study was to assess the presence of anti-SARS-CoV-2 IgA in the saliva of 95 subjects vaccinated with a booster dose and different combinations of vaccines, including mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech), and Vaxzevria (AstraZeneca). The results showed the presence of a mucosal response in 93.7% of vaccinated subjects, with a mean IgA titer of 351.5 ± 31.77 U/mL, strongly correlating with the serum anti-SARS-CoV-2 IgG titer (p < 0.0001). No statistically significant differences emerged between the vaccine types, although the salivary IgA titer appeared slightly higher after receiving a booster dose of the mRNA-1273 vaccine (Moderna) following two doses of BNT162b2 (Pfizer-BioNTech), compared to the other vaccine combinations. These data confirm what was previously reported at the eye level and suggest that monitoring salivary IgA may be a useful tool for driving forward vaccine design and surveillance strategies, potentially leading to novel routes of vaccine administration and boosting.Keywords
Funding Information
- University of Ferrara (FAR-2022)
This publication has 31 references indexed in Scilit:
- Protection of BNT162b2 Vaccine Booster against Covid-19 in IsraelNew England Journal of Medicine, 2021
- Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional StudyFrontiers in Microbiology, 2021
- In Nasal Mucosal Secretions, Distinct IFN and IgA Responses Are Found in Severe and Mild SARS-CoV-2 InfectionFrontiers in Immunology, 2021
- Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19Journal of Allergy and Clinical Immunology, 2021
- IgA dominates the early neutralizing antibody response to SARS-CoV-2Science Translational Medicine, 2021
- Anti-SARS-Cov-2 IgA Response in Tears of COVID-19 PatientsBiology, 2020
- A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interactionNature Communications, 2020
- Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy pictureBMC Microbiology, 2020
- The Effects of Secretory IgA in the Mucosal Immune SystemBioMed Research International, 2020
- An improved bind-n-seq strategy to determine protein-DNA interactions validated using the bacterial transcriptional regulator YipRBMC Microbiology, 2020